The FDA on March 22, 2024, approved ELAHERE® (Mirvetuximab soravtansine-gynx) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. ELAHERE® is a product of ImmunoGen, Inc. [now a part of AbbVie]).
Bottom Ad
Advertisement
Subscribe
